Value of Somatostatin Receptor Scintigraphy (SRS) in Patients with Appendiceal Neuroendocrine Neoplasms (ANEN) Based on Clinical Follow-up and Results of NETest Abstract #2282

Introduction: Neuroendocrine neoplasms of the appendix (ANEN) are one of the most commonly identified gastroentropancreatic tumours (GEP). The aim of this retrospective study was to review the value of Somatostatin Receptor Scintigraphy (SRS) in staging and imaging follow-up of patients with confirmed ANEN, NENG1 and NENG2 in single institution.
Aim(s): The aim was to compare results of SRS to a new approach using PCR-based test of specific circulating neuroendocrine tumour transcripts (NETest) to exclude presence of active disease.
Materials and methods: Overall, 90 patients with confirmed ANEN. Whole body (WB) and SPECT/CT SRS using 99mTc HYNICTOC was performed to assess disease extent before/after additional surgery and imaging follow-up. NETest were measured in selected 22 subjects.
Conference: 15th Annual ENETS conference (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Sonia Konsek

To read results and conclusion, please login ...

Further abstracts you may be interested in

#12 Chromogranin A as a predictor of progression, regression or stable disease in ileo-cecal (midgut) carcinoid tumors
Introduction: A general characteristic for NETs is their expression of certain proteins, such as chromogranin A (CgA), which is released from the dense core vesicles of NE cells, occasionally together with cell specific hormones, such as gastrin and serotonin. Plasma CgA seems to be closely related to tumor burden of intestinal carcinoid tumors in humans.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Kenneth Jensen
#13 Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic carcinoma
Introduction: Pancreatic endocrine tumors (pNETs) are rare but are among the most common neuroendocrine neoplasms of the abdomen. At diagnosis, many of them are already advanced and difficult to treat.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Daniel Kaemmerer
#26 Molecular imaging of gastroenteropancreatic neuroendocrine tumours with Ga-68 DOTANOC PET/CT and correlation with an immunhistochemical quantification of somatostatin receptors using novel monoclonal and polyclonal antibodies
Introduction: Receptor PET/CT with somatostatin analogues marked with Gallium-68 (SMS-R-PET/CT) is currently the golden standard in diagnosing gastroenteropancreatic neuroendocrine tumors (GEP-NET), which are known for an overexpression of somatostatin receptors (SSTRs).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Daniel Kaemmerer
#56 Somatostatinreceptor scintigraphy with Tc-99m-tektrotyd in patients with neuroendocrine tumors: correlation with immunohistochemistry
Introduction: Somatostatin receptor scintigraphy (STRS) with Tc-99m-tektrotyd has been used in the past few years for diagnosis and staging of neuroendocrine tumors (NETs). A number of clinicopathologic criteria proved to be useful predictors of malignant behavior of these tumors. Immunohistochemical markers for NETs include cell proliferation (Ki-67 index) and neuroendocrine markers such as chromogranin A (CgA) and synaptophysin.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Prof Margarida Rodrigues
#107 Results of the Gastroenteropancreatic NETs Spanish Registry in the 2001-2010 period
Introduction: Gastroenteropancreatic neuroendocrine tumors (GEPNETs) are infrequent and heterogeneous neoplasms that have conditioned the lack of verified epidemiologic data.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Jaume Capdevila